Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print June 28, 2006, doi:10.1212/01.wnl.0000231510.89311.8b)
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parkinson, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parkinson, N.
Related Collections
Right arrow Amyotrophic lateral sclerosis
Right arrow All Genetics
N. Parkinson, PhD*, P. G. Ince, MD*, M. O. Smith, BSc, R. Highley, PhD, G. Skibinski, PhD, P. M. Andersen, MD, K. E. Morrison, PhD, H. S. Pall, MD, O. Hardiman, PhD, J. Collinge, MD, P. J. Shaw, MD*, EM C. Fisher, PhD* on behalf of the MRC Proteomics in ALS Study and the FReJA Consortium{dagger}

From the MRC Prion Unit (N.P., G.S., J.C.) and Department of Neurodegenerative Disease (J.C., E.M.C.F.), Institute of Neurology, University College London, London, UK; Academic Units of Pathology (P.G.I., M.O.S., R.H.) and Neurology (P.J.S.), University of Sheffield, Sheffield, UK; Department of Neurology and Clinical Neuroscience (P.M.A.), Umeå University Hospital, Umeå, Sweden; Division of Neuroscience (K.E.M., H.S.P.), University of Birmingham, Birmingham, UK; and Department of Neurology (O.H.), Beaumont Hospital, Dublin, Eire.


Figure 137
View larger version (101K):

[in a new window]
 
Figure. Photomicrographs of motor system regions from Patient 1. (A) Motor cortex showing intact Betz cells. (B) Low-power view of spinal anterior horn showing numerous motor neuron compact inclusions typical of ALS. These lesions were immunoreactive both to ubiquitin and p62/sequestosome 1 but negative for tau, neurofilament, and {alpha}-synuclein. (C) Compact inclusion in a spinal cord motor neuron. (D) Motor cortex showing numerous cell profiles immunoreactive for p62/sequestosome1. (E) At high power, these cortical inclusion bodies show coiled body morphology. They were not demonstrated by conventional ubiquitin immunocytochemistry or to antibodies to tau, neurofilament, and {alpha}-synuclein. Double-labeling immunocytochemistry was performed using either SMI32 (neurons), glial fibrillary acidic protein (astrocytes), CD68 (microglia), or carbonic anhydrase II (oligodendroglia) and p62/sequestosome 1 to identify the cell type involved by coiled body inclusion formation. (F) Coiled bodies immunostained for p62/sequestosome 1. (G) As in F under fluorescence illumination showing cell profiles stained by carbonic anhydrase II. (H) Merged images of parts F and G showing colocalization of coiled bodies to oligodendroglia. (Cresyl fast violet [A], immunoperoxidase [3,3'-diamino-benizidine chromogen] forp62/sequestosome 1 [B, C, D, E, F, H]; immunofluorescence [Texas Red for carbonic anhydrase II] [G, H]; magnification: x2 [B,D]; x40 [A, C, E, F, G, H]).

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.